Skip to content

Study · Animal study (in vivo) · mouse · 2025

2 results

The kisspeptin analog C6 reverses reproductive dysfunction in a mouse model of hyperprolactinemia.

Beaudou C, Sionneau L, Lomet D, Robert V, Gaillard PJ, Aucagne V, Dardente H, Beltramo M, Hellier V

Reproduction (Cambridge, England)17 Mar 2025Cited by 1 (Europe PMC)

PMID40062901 (opens in a new tab)PMCIDPMC11949517 (opens in a new tab)DOI10.1530/rep-25-0036 (opens in a new tab)PepBankPUB-40062901
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

In briefKisspeptin has been shown to be tightly associated with hyperprolactinemia. This study shows that similar to kisspeptin, its analog C6 produces a reversal of HPRL estrus cycle and ovulation disruption.AbstractHPRL, characterized by elevated prolactin levels, disrupts the hypothalamic-pituitary-gonadal axis, leading to reproductive dysfunctions such as menstrual irregularities, anovulation and infertility. Current treatments rely on dopamine agonists but are limited by side effects and resistance. Kisspeptin (Kp), a key neuropeptide regulating the reproductive function, offers potential as an alternative therapy. However, Kp's short half-life requires impractical administration regimens. To address this, we developed a synthetic Kp analog, C6, with enhanced pharmacokinetics. This study evaluated the effects of C6 compared to Kp in a mouse model of HPRL. Mice received subcutaneous PRL injections for 21 days to induce HPRL, followed by daily or alternate-day intraperitoneal administration of Kp10, C6 or vehicle. Estrous cyclicity, luteinizing hormone (LH) secretion, ovarian histology and hypothalamic gene expression were analyzed. As expected, the HPRL treatment blocked estrous activity, which was restored by both Kp10, the shortest bioactive isoform of Kp, and C6. Histological analysis revealed increased corpora lutea in Kp10- and C6-treated groups, indicating restored ovulation. C6 demonstrated equivalent efficacy to Kp10 in mitigating HPRL-induced reproductive dysfunctions, offering a promising alternative therapy. Future investigations should further explore the mechanistic advantages of C6, particularly its role in LH regulation, to optimize treatment strategies for HPRL-related reproductive disorders.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with prolactin-induced hyperprolactinemia, Kp10 restored estrous activity that the prolactin treatment had blocked.

    In plain wordsIn mice with high prolactin, Kp10 brought back the estrous cycle that high prolactin had stopped.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseEstrous cyclicity
    Study

    mousen: not reported in source

    prolactin-induced hyperprolactinemia (HPRL)
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    As expected, the HPRL treatment blocked estrous activity, which was restored by both Kp10, the shortest bioactive isoform of Kp, and C6.
    1 context sentence
    Summary · context
    Mice received subcutaneous PRL injections for 21 days to induce HPRL, followed by daily or alternate-day intraperitoneal administration of Kp10, C6 or vehicle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with prolactin-induced hyperprolactinemia, Kp10 increased the number of corpora lutea, which indicates restored ovulation.

    In plain wordsIn mice with high prolactin, Kp10 led to more corpora lutea in the ovaries, a sign that ovulation returned.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseCorpora lutea in ovaries
    Study

    mousen: not reported in source

    prolactin-induced hyperprolactinemia (HPRL)
    Comparator
    Vehicle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Histological analysis revealed increased corpora lutea in Kp10- and C6-treated groups, indicating restored ovulation.
    1 context sentence
    Summary · context
    Mice received subcutaneous PRL injections for 21 days to induce HPRL, followed by daily or alternate-day intraperitoneal administration of Kp10, C6 or vehicle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.